The cannabinoid CB1receptor and the endocannabinoid anandamide: possible antidepressant targets-Reference-Cited by-同舟云学术

The cannabinoid CB1receptor and the endocannabinoid anandamide: possible antidepressant targets

Published:2008-10-14 Issue:11 Volume:12 Page:1347-1366
ISSN:1472-8222
Container-title:Expert Opinion on Therapeutic Targets
language:en
Short-container-title:Expert Opinion on Therapeutic Targets

Author:

Bambico Francis Rodriguez,Gobbi Gabriella

Publisher

Informa Healthcare

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/14728222.12.11.1347

Reference159 articles.

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th edition. Washington, DC: American Psychiatric Association; 2000

2. Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication

3. New approaches to antidepressant drug discovery: beyond monoamines

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intervention effects of Naoxintong capsules on psychological and cardiac status in depressed rats after heart failure;Science of Traditional Chinese Medicine;2024-09-04

2. The chronic pharmacological antagonism of the CB1 receptor is not involved in the behavioral effects of antidepressants administered in mice submitted to chronic unpredictable stress;Behavioural Brain Research;2023-07

3. Medicinal cannabis for pain: Real-world data on three-month changes in symptoms and quality of life;Drug Science, Policy and Law;2023-01

4. Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: A novel target for upcoming antidepressants;Pharmacology Research & Perspectives;2022-08-26

5. Cannabinoids—Perspectives for Individual Treatment in Selected Patients: Analysis of the Case Series;Biomedicines;2022-08-02